EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD

Jonathan Arnold, Deeksha Acharya, Hetal Boricha, Himal Chapagain, Aleesha Kainat, Allison Bradley, Jong-Hyeon Jeong, Kevin A Townsend, Mohammad B Ateya, David A DeMicco, YousefAlish, Michael J Becich und 13 weitere

American Journal of Preventive Cardiology · 2025-09 · 23 · 101067

DOI: 10.1016/j.ajpc.2025.101067 ↗

Kurz gefasst

Leitlinie in der Zeitschrift American Journal of Preventive Cardiology, 2025-09. Verfasst von Jonathan Arnold und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh School of Medicine, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The value of lipid lowering therapy (LLT) for prevention of atherosclerotic cardiovascular disease (ASCVD) is well understood. American College of Cardiology and American Heart Association guidelines recommend statin therapy for secondary and high-risk primary ASCVD prevention. Prior studies have identified incomplete uptake of these guidelines in specific practice settings or patient populations. Here we characterized real-world LLT prescribing relative to guideline recommendations across seven US health systems.

Methods

Cross-sectional analyses of records from the PaTH Clinical Research Network focused on three cohorts: adults with ASCVD (ASCVD cohort), those aged 40-75 without ASCVD but with diabetes mellitus (DM cohort), and those not in either prior category but with a history of low-density lipoprotein (LDL-C) >190 mg/dl (LDL-C cohort). We describe patient characteristics, patterns of care, lipid values, and documented LLT within each cohort and variation between health systems.

Results

We identified 240,625 patients within the ASCVD cohort (LDL-C mean 86, SD 40 mg/dL), 113,662 patients in the DM cohort (LDL-C mean 93, SD 37 mg/dL), and 11,276 patients in the LDL-C cohort (LDL-C mean 208, SD 33 mg/dL. Among ASCVD cohort members, 37 % achieved the target LDL-C 160 mg/dl, 44 % were on statin therapy and 16 % on high-intensity statin therapy. There was significant variability in documented LLT between health systems.

Conclusions

In this real-world descriptive study across multiple health systems for patients meeting criteria for secondary or high-risk primary ASCVD prevention, most patients had no documented high-intensity statin prescriptions and did not meet LDL-C targets. There was significant variability in care across health systems. Opportunities remain for improvement in guideline adherence to reduce ASCVD risk.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular diseasesDrug prescriptionsDrug utilizationHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLDL CholesterolLipid lowering therapyPractice patternsPrimary preventionReal-world evidenceSecondary preventionStatins

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh School of Medicine, USA.
  • UPMC McKeesport, USA.
  • University of Pittsburgh Medical Center McKeesport, USA.
  • Department of Biomedical Informatics, University of Pittsburgh School of Medicine, USA.
  • Graduate School of Public Health. University of Pittsburgh, USA.
  • Pfizer Inc, USA.

Förderung

  • Pfizer

Zitieren

APA

Arnold, J., Acharya, D., Boricha, H., Chapagain, H., Kainat, A., Bradley, A., Jeong, J. H., Townsend, K. A., Ateya, M. B., DeMicco, D. A., YousefAlish, Becich, M. J., Chuang, C. H., Fernandez, S. A., Ford, D. E., Hwang, W., Kirchner, H. L., Morgan, R., Paranjape, A., …, & McTigue, K. M. (2025). Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD. American Journal of Preventive Cardiology, 23, 101067. https://doi.org/10.1016/j.ajpc.2025.101067

Vancouver

Arnold J, Acharya D, Boricha H, Chapagain H, Kainat A, Bradley A, et al. Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD. American Journal of Preventive Cardiology. 2025;23:101067. doi:10.1016/j.ajpc.2025.101067

BibTeX
@article{Arnold2025,
  author = {Arnold, Jonathan and Acharya, Deeksha and Boricha, Hetal and Chapagain, Himal and Kainat, Aleesha and Bradley, Allison and Jeong, Jong-Hyeon and Townsend, Kevin A and Ateya, Mohammad B and DeMicco, David A and YousefAlish and Becich, Michael J and Chuang, Cynthia H and Fernandez, Soledad A and Ford, Daniel E and Hwang, Wenke and Kirchner, H Lester and Morgan, Richard and Paranjape, Anuradha and Thomas, Neena A and Williams, David A and RozelleHegeman-Dingle and McLeod, Euan and Saccone, Phillip A and McTigue, Kathleen M},
  title = {Real-world prescribing in accordance to ACC/AHA guidelines for lipid-lowering therapy in high-risk primary and secondary prevention of ASCVD},
  journal = {American Journal of Preventive Cardiology},
  year = {2025},
  volume = {23},
  pages = {101067},
  doi = {10.1016/j.ajpc.2025.101067}
}
Kostenlos starten →